Search Results 1121-1130 of 19307 for Hemoglobin

1. A Study of JNJ-68284528, a Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   ECOG Performance Status grade of 0 or 1. Clinical laboratory values meeting the following criteria during the Screening Phase: HEMOTOLOGY. Hemoglobin. ≥ 8.0 ...

2. Actinium Therapy For Late-stage Aggressive Sarcomas - Mayo Clinic

   Hemoglobin ≥ 8 g/dL 4. Total bilirubin level ≤ 1.5 × upper limit of normal (ULN). 5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ...

3. Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma - Mayo Clinic

   ... hemoglobin level that remains above ≥ 9 g/L for at least 2 weeks). Hematology; Platelet count. < 100 × 10^9/L. Hemoglobin. < 9 g/L. ANC. < 1.5 × 10^9/L.

4. A Study to Find the Genetics and Metabolism Dysfunction for Familial Partial Lipodystrophy - Mayo Clinic

   Hemoglobin < 10g%. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for the most up-to-date information ...

5. A Study Using Chemotherapy Followed by Radiation Therapy in Treating Younger Patients with Newly Diagnosed Localized Central Nervous System Germ Cell Tumors - Mayo Clinic

   Hemoglobin ≥ 8.0 g/dL (may receive red blood cell [RBC] transfusions); Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m²; OR serum creatinine ...

6. Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III - Mayo Clinic

   Hemoglobin less than 12 mg/dL. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for the most up-to-date ...

7. A Study to Assess the Efficacy and Safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) - Mayo Clinic

   duration of the study and 30 days following the last dose of study drug. Exclusion Criteria: - Subject has severe anemia defined as hemoglobin <8.0 g/dL (<4.9 ...

8. Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes - Mayo Clinic

   Known history of hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the ...

9. A Study To Evaluate The Efficacy And Safety Of GDC-8264 In Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) And Major Adverse Kidney Events (MAKE) - Mayo Clinic

   ... hemoglobin <10 milligrans/ deciliters (mg/dL)} 3. Stable kidney function with no known episodes of AKI within 2 weeks of screening. Exclusion Criteria: 1 ...

10. A Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS) - Mayo Clinic

    Hemoglobin ≥ 10 g/dL. Patient must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria.